July 29, 2021: Racial disparities in hospitalization rates; city-specific mortality demographics; effects of traditional risk factors vs. antiretrovirals on weight gain and cardiovascular risk.
July 22, 2021: How HIV criminalization laws may reduce disclosure; anxiety and housing satisfaction; poor immune response to delayed ART; the U.S.'s HIV testing mountain.
HIV status is a risk factor for worse COVID-19 outcomes, but it remains uncertain the extent to which antiretroviral therapy, viral load, and CD4 count can reduce that risk, according to a new flurry of research presented at IAS 2021.
The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.
Our quick summaries of breaking conference research include new study findings on injectable long-acting cabotegravir/rilpivirine and the latest on lenacapavir, a twice-yearly injectable medication in the pipeline.
As new data attest, there is no one-size-fits-all approach to getting people retained in care; an individualized approach is best, if the health care facility can manage it.
July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.
A recent study reaffirms that starting antiretroviral therapy soon after HIV diagnosis leads to faster viral suppression.
Three women of color—an HIV physician, a public health researcher, and a sexual health advisor—speak about the role of providers in improving services and experiences for women.
July 8, 2021: Trends among heavily treatment-experienced PLWH; a new look at peripheral neuropathy factors; heart transplantation in PLWH; complications following successful HCV treatment.